Cargando…

Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases

BACKGROUND: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by APEX technology and direct Sanger sequencing of known genes. However, these meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Audo, Isabelle, Bujakowska, Kinga M, Léveillard, Thierry, Mohand-Saïd, Saddek, Lancelot, Marie-Elise, Germain, Aurore, Antonio, Aline, Michiels, Christelle, Saraiva, Jean-Paul, Letexier, Mélanie, Sahel, José-Alain, Bhattacharya, Shomi S, Zeitz, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352121/
https://www.ncbi.nlm.nih.gov/pubmed/22277662
http://dx.doi.org/10.1186/1750-1172-7-8
_version_ 1782232851455934464
author Audo, Isabelle
Bujakowska, Kinga M
Léveillard, Thierry
Mohand-Saïd, Saddek
Lancelot, Marie-Elise
Germain, Aurore
Antonio, Aline
Michiels, Christelle
Saraiva, Jean-Paul
Letexier, Mélanie
Sahel, José-Alain
Bhattacharya, Shomi S
Zeitz, Christina
author_facet Audo, Isabelle
Bujakowska, Kinga M
Léveillard, Thierry
Mohand-Saïd, Saddek
Lancelot, Marie-Elise
Germain, Aurore
Antonio, Aline
Michiels, Christelle
Saraiva, Jean-Paul
Letexier, Mélanie
Sahel, José-Alain
Bhattacharya, Shomi S
Zeitz, Christina
author_sort Audo, Isabelle
collection PubMed
description BACKGROUND: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by APEX technology and direct Sanger sequencing of known genes. However, these methods are time consuming, expensive and unable to provide a result if the patient carries a new gene mutation. In addition, multiplicity of phenotypes associated with the same gene defect may be overlooked. METHODS: To overcome these challenges, we designed an exon sequencing array to target 254 known and candidate genes using Agilent capture. Subsequently, 20 DNA samples from 17 different families, including four patients with known mutations were sequenced using Illumina Genome Analyzer IIx next-generation-sequencing (NGS) platform. Different filtering approaches were applied to identify the genetic defect. The most likely disease causing variants were analyzed by Sanger sequencing. Co-segregation and sequencing analysis of control samples validated the pathogenicity of the observed variants. RESULTS: The phenotype of the patients included retinitis pigmentosa, congenital stationary night blindness, Best disease, early-onset cone dystrophy and Stargardt disease. In three of four control samples with known genotypes NGS detected the expected mutations. Three known and five novel mutations were identified in NR2E3, PRPF3, EYS, PRPF8, CRB1, TRPM1 and CACNA1F. One of the control samples with a known genotype belongs to a family with two clinical phenotypes (Best and CSNB), where a novel mutation was identified for CSNB. In six families the disease associated mutations were not found, indicating that novel gene defects remain to be identified. CONCLUSIONS: In summary, this unbiased and time-efficient NGS approach allowed mutation detection in 75% of control cases and in 57% of test cases. Furthermore, it has the possibility of associating known gene defects with novel phenotypes and mode of inheritance.
format Online
Article
Text
id pubmed-3352121
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33521212012-05-16 Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases Audo, Isabelle Bujakowska, Kinga M Léveillard, Thierry Mohand-Saïd, Saddek Lancelot, Marie-Elise Germain, Aurore Antonio, Aline Michiels, Christelle Saraiva, Jean-Paul Letexier, Mélanie Sahel, José-Alain Bhattacharya, Shomi S Zeitz, Christina Orphanet J Rare Dis Research BACKGROUND: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by APEX technology and direct Sanger sequencing of known genes. However, these methods are time consuming, expensive and unable to provide a result if the patient carries a new gene mutation. In addition, multiplicity of phenotypes associated with the same gene defect may be overlooked. METHODS: To overcome these challenges, we designed an exon sequencing array to target 254 known and candidate genes using Agilent capture. Subsequently, 20 DNA samples from 17 different families, including four patients with known mutations were sequenced using Illumina Genome Analyzer IIx next-generation-sequencing (NGS) platform. Different filtering approaches were applied to identify the genetic defect. The most likely disease causing variants were analyzed by Sanger sequencing. Co-segregation and sequencing analysis of control samples validated the pathogenicity of the observed variants. RESULTS: The phenotype of the patients included retinitis pigmentosa, congenital stationary night blindness, Best disease, early-onset cone dystrophy and Stargardt disease. In three of four control samples with known genotypes NGS detected the expected mutations. Three known and five novel mutations were identified in NR2E3, PRPF3, EYS, PRPF8, CRB1, TRPM1 and CACNA1F. One of the control samples with a known genotype belongs to a family with two clinical phenotypes (Best and CSNB), where a novel mutation was identified for CSNB. In six families the disease associated mutations were not found, indicating that novel gene defects remain to be identified. CONCLUSIONS: In summary, this unbiased and time-efficient NGS approach allowed mutation detection in 75% of control cases and in 57% of test cases. Furthermore, it has the possibility of associating known gene defects with novel phenotypes and mode of inheritance. BioMed Central 2012-01-25 /pmc/articles/PMC3352121/ /pubmed/22277662 http://dx.doi.org/10.1186/1750-1172-7-8 Text en Copyright ©2012 Audo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Audo, Isabelle
Bujakowska, Kinga M
Léveillard, Thierry
Mohand-Saïd, Saddek
Lancelot, Marie-Elise
Germain, Aurore
Antonio, Aline
Michiels, Christelle
Saraiva, Jean-Paul
Letexier, Mélanie
Sahel, José-Alain
Bhattacharya, Shomi S
Zeitz, Christina
Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
title Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
title_full Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
title_fullStr Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
title_full_unstemmed Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
title_short Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
title_sort development and application of a next-generation-sequencing (ngs) approach to detect known and novel gene defects underlying retinal diseases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352121/
https://www.ncbi.nlm.nih.gov/pubmed/22277662
http://dx.doi.org/10.1186/1750-1172-7-8
work_keys_str_mv AT audoisabelle developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT bujakowskakingam developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT leveillardthierry developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT mohandsaidsaddek developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT lancelotmarieelise developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT germainaurore developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT antonioaline developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT michielschristelle developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT saraivajeanpaul developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT letexiermelanie developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT saheljosealain developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT bhattacharyashomis developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases
AT zeitzchristina developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases